药物性肝脂肪性肝炎。
Drug-induced steatohepatitis.
机构信息
Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Medical Center, Virginia Commonwealth University, MCV Box 980341, Richmond, VA 23298-0341, USA.
出版信息
Clin Liver Dis. 2013 Nov;17(4):533-46, vii. doi: 10.1016/j.cld.2013.07.012. Epub 2013 Sep 4.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in the United States. The term NALFD was first used by Ludwig in 1980 to describe the presence of hepatic steatosis and steatohepatitis in a series of patients with no identifiable cause. Since then, our insight into the pathogenesis of NAFLD has expanded significantly. We now know that NAFLD is closely related to metabolic syndrome and chronic low-grade inflammation. In the following review, the authors summarize the current evidence about drugs that lead to hepatic steatosis and steatohepatitis and pathogenic mechanisms thereof.
摘要
非酒精性脂肪性肝病（NAFLD）是目前美国最常见的慢性肝病病因。NALFD 一词最早由 Ludwig 于 1980 年提出，用于描述一系列无明确病因的患者中存在的肝脂肪变性和脂肪性肝炎。此后，我们对 NAFLD 发病机制的认识显著扩展。我们现在知道，NAFLD 与代谢综合征和慢性低度炎症密切相关。在下面的综述中，作者总结了导致肝脂肪变性和脂肪性肝炎的药物及其发病机制的现有证据。
相似文献
1
Drug-induced steatohepatitis.药物性肝脂肪性肝炎。
Clin Liver Dis. 2013 Nov;17(4):533-46, vii. doi: 10.1016/j.cld.2013.07.012. Epub 2013 Sep 4.
2
Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease.药物性脂肪性肝炎：一种常见疾病的罕见病因
Biomed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905. Epub 2015 Jul 26.
3
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use.药物性脂肪性肝炎导致肝硬化：胺碘酮使用的长期毒性
Semin Liver Dis. 2009 Nov;29(4):423-8. doi: 10.1055/s-0029-1240011. Epub 2009 Oct 13.
4
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.药物性肝脂肪病（DIFLD）：对临床、生化和组织病理学数据的综合分析，以识别机制并与当前不良结局途径保持一致。
Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203.
5
Chemotherapy-associated steatohepatitis.化疗相关性脂肪性肝炎。
Ann Hepatol. 2020 Nov-Dec;19(6):597-601. doi: 10.1016/j.aohep.2019.11.012. Epub 2020 Jan 30.
6
Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.综述文章：非酒精性脂肪性肝病背景下的药物性肝损伤——病理生理学和临床综合观点。
Aliment Pharmacol Ther. 2018 Nov;48(9):892-913. doi: 10.1111/apt.14952. Epub 2018 Sep 7.
7
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.非酒精性脂肪性肝病、肥胖症与代谢综合征。
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Epub 2014 Jul 11.
8
Nonalcoholic fatty liver disease.非酒精性脂肪性肝病
Minerva Med. 2008 Dec;99(6):583-93.
9
Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.非酒精性脂肪性肝病/肝炎：流行病学、发病机制、临床表现和治疗。
Dig Dis. 2012;30(2):158-62. doi: 10.1159/000336669. Epub 2012 Jun 20.
10
[Steatosis and steatohepatitis in diabetic patient].[糖尿病患者的脂肪变性和脂肪性肝炎]
Vnitr Lek. 2011 Apr;57(4):364-7.
引用本文的文献
1
Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.药物性肝脂肪病（DIFLD）：对临床、生化和组织病理学数据的综合分析，以识别机制并与当前不良结局途径保持一致。
Int J Mol Sci. 2024 May 10;25(10):5203. doi: 10.3390/ijms25105203.
2
The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis.神经介素U水平与非酒精性脂肪性肝病的关联：一项对比分析。
Heliyon. 2024 Mar 5;10(5):e27291. doi: 10.1016/j.heliyon.2024.e27291. eCollection 2024 Mar 15.
3
Non-invasive differentiation of hepatic steatosis and steatohepatitis in a mouse model using nitroxyl radical as an MRI-contrast agent.在小鼠模型中使用硝酰自由基作为磁共振成像造影剂对肝脂肪变性和脂肪性肝炎进行无创鉴别。
Toxicol Rep. 2023 Dec 9;12:1-9. doi: 10.1016/j.toxrep.2023.12.002. eCollection 2024 Jun.
4
Correlation between Cumulative Methotrexate Dose, Metabolic Syndrome and Hepatic Fibrosis Detected by FibroScan in Rheumatoid Arthritis Patients.类风湿关节炎患者累积甲氨蝶呤剂量、代谢综合征与 FibroScan 检测肝纤维化的相关性。
Medicina (Kaunas). 2023 May 26;59(6):1029. doi: 10.3390/medicina59061029.
5
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus.甲氨蝶呤治疗皮肤病的真实世界经验：一项意大利德尔菲共识。
Dermatol Ther (Heidelb). 2023 Jun;13(6):1219-1241. doi: 10.1007/s13555-023-00930-2. Epub 2023 May 21.
6
Non-alcoholic fatty liver disease in hemochromatosis probands with iron overload and HFE p.C282Y/p.C282Y.血色病铁过载且 HFE p.C282Y/p.C282Y 杂合子先证者中的非酒精性脂肪性肝病
BMC Gastroenterol. 2023 Apr 28;23(1):137. doi: 10.1186/s12876-023-02763-x.
7
Fatty liver disease that is neither metabolic nor alcoholic.非代谢性或酒精性脂肪性肝病。
Hum Pathol. 2023 Nov;141:212-221. doi: 10.1016/j.humpath.2023.01.003. Epub 2023 Jan 24.
8
Potential of the zebrafish (Danio rerio) embryo test to discriminate between chemicals of similar molecular structure-a study with valproic acid and 14 of its analogues.斑马鱼（Danio rerio）胚胎试验在区分具有相似分子结构的化学物质方面的潜力——以丙戊酸及其 14 种类似物为例的研究。
Arch Toxicol. 2022 Nov;96(11):3033-3051. doi: 10.1007/s00204-022-03340-z. Epub 2022 Aug 3.
9
Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods.线粒体作为肝毒性和药物性肝损伤的靶点：分子机制和检测方法。
Int J Mol Sci. 2022 Mar 18;23(6):3315. doi: 10.3390/ijms23063315.
10
Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update.药物性非酒精性脂肪性肝病和非酒精性脂肪性肝炎的详细分子机制：最新进展
Biomedicines. 2022 Jan 17;10(1):194. doi: 10.3390/biomedicines10010194.
本文引用的文献
1
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.结直肠癌肝转移的全身细胞毒性和生物治疗：专家共识声明。
HPB (Oxford). 2013 Feb;15(2):106-15. doi: 10.1111/j.1477-2574.2012.00558.x. Epub 2012 Sep 24.
2
Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation.由于胸苷类似物导致的自噬抑制是导致肝细胞功能障碍和脂质积累的新机制。
AIDS. 2012 Oct 23;26(16):1995-2006. doi: 10.1097/QAD.0b013e32835804f9.
3
Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity.脂质组学分析揭示了脂肪酸氧化在可卡因诱导的肝毒性中的保护作用。
J Lipid Res. 2012 Nov;53(11):2318-30. doi: 10.1194/jlr.M027656. Epub 2012 Aug 19.
4
HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.HIV抗逆转录病毒疗法引起的肝脏、胃肠道和胰腺损伤。
Int J Hepatol. 2012;2012:760706. doi: 10.1155/2012/760706. Epub 2012 Mar 11.
5
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会、美国胃肠病学会和美国胃肠病协会实践指南
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
6
Central role of mitochondria in drug-induced liver injury.线粒体在药物性肝损伤中的核心作用。
Drug Metab Rev. 2012 Feb;44(1):34-87. doi: 10.3109/03602532.2011.604086. Epub 2011 Sep 6.
7
Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.诊断非酒精性脂肪性肝病患者的脂肪性肝炎并预测肝脏相关死亡率：两个不同的概念。
Hepatology. 2011 Jun;53(6):1792-4. doi: 10.1002/hep.24403.
8
The role of oxidative stress in non-alcoholic steatohepatitis.氧化应激在非酒精性脂肪性肝炎中的作用。
Clin Chim Acta. 2011 Jul 15;412(15-16):1297-305. doi: 10.1016/j.cca.2011.04.013. Epub 2011 Apr 16.
9
Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.胺碘酮和四环素诱导的泡状脂肪变性与 HepaRG 细胞中脂肪生成基因的上调有关。
Hepatology. 2011 Jun;53(6):1895-905. doi: 10.1002/hep.24290. Epub 2011 May 2.
10
Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis.他莫昔芬通过激活脂肪酸合成诱导小鼠肝脏三酰基甘油积累。
Hepatology. 2010 Oct;52(4):1258-65. doi: 10.1002/hep.23813.
Zotero 插件